Champions Oncology, Inc. develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The company, through its Tumorgraft Technology Platform, provides Personalized Oncology Solutions (POS) that assist physicians in developing personalized treatment options for cancer patients through tumor specific data obtained from drug panels and related personalized oncology services. The company also offers POS products, including personalized tumor boards that are designed to provide access to oncologists with expertise in particular tumor types; and provides access to gene sequencing that analyzes the genetic makeup of patient's tumor for the purpose of identifying potentially useful drugs. In addition, it offers Translational Oncology Solutions, including a preclinical Tumorgraft platform to pharmaceutical and biotechnology companies. Champions Oncology, Inc. markets its products through Internet, word of mouth, and sales force to patients and physicians. The company was formerly known as Champions Biotechnology, Inc. and changed its name to Champions Oncology, Inc. in April 2011 to reflect its new focus on developing technologies to personalize the development and use of oncology drugs. Champions Oncology, Inc. was incorporated in 1985 and is headquartered in Hackensack, New Jersey.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Phone201-808-8400
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$20.24 million
Profitability
Miscellaneous
Employees92
Next Earnings DateN/A
OptionableNot Optionable
Champions Oncology (NASDAQ:CSBR) Frequently Asked Questions
What is Champions Oncology's stock symbol?
Champions Oncology trades on the NASDAQ under the ticker symbol "CSBR."
How were Champions Oncology's earnings last quarter?
Champions Oncology Inc (NASDAQ:CSBR) issued its quarterly earnings results on Monday, December, 17th. The biotechnology company reported $0.03 earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of $0.04 by $0.01. The biotechnology company had revenue of $6.69 million for the quarter, compared to the consensus estimate of $6.35 million. Champions Oncology had a negative return on equity of 22.94% and a negative net margin of 1.16%. View Champions Oncology's Earnings History.
What guidance has Champions Oncology issued on next quarter's earnings?
Champions Oncology updated its FY 2019 earnings guidance on Monday, March, 18th. The company provided EPS guidance of for the period. The company issued revenue guidance of $24.289 million, compared to the consensus revenue estimate of $25.93 million.
What price target have analysts set for CSBR?
4 equities research analysts have issued 12 month price targets for Champions Oncology's shares. Their forecasts range from $10.00 to $17.00. On average, they expect Champions Oncology's share price to reach $13.00 in the next twelve months. This suggests a possible upside of 28.8% from the stock's current price. View Analyst Price Targets for Champions Oncology.
What is the consensus analysts' recommendation for Champions Oncology?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Champions Oncology in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Champions Oncology.
What are Wall Street analysts saying about Champions Oncology stock?
Here are some recent quotes from research analysts about Champions Oncology stock:
- 1. According to Zacks Investment Research, "Champions Oncology, Inc., formerly known as Champions Biotechnology, Inc., engages in the development of advanced technology solutions to personalize the development and use of oncology drugs. The Company's Tumorgraft Technology Platform is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune deficient mice followed by propagation of the resulting engraftments. This technology can evaluate tumor sensitivity/resistance to various single, combination standard and novel chemotherapy agents. Champions Oncology, Inc. is based in Baltimore, Maryland. " (3/18/2019)
- 2. National Securities analysts commented, "Low risk way to invest in the development of oncology drugs: Champions Oncology (CSBR) sells products and services to pharmaceutical and biotechnology customers to help them quickly eliminate non-promising drugs, and determine the proper indications, dosage, and patient sub-populations for promising drug candidates. We believe that the company will continue to benefit from the expanding pipeline of oncology drugs.
Sustained profitability: Champions reported two consecutive profitable quarters in F1Q19 and F2Q19. We believe that CSBR will continue to remain profitable in the second half of F2019 based on revenue growth of 34.1%, a rebound in gross margins to over 50%, and a solid control of operating expenses. In F2020, we project that revenues will grow by 22.7%, and operating margins will reach over 12.3% (compared to 5.3% in FY 2019) resulting in GAAP net income of $3.9 million ($0.27 EPS), up from $1.4 million ($0.10 EPS) in F2019.
Expanding Cash Flow/Solid Balance Sheet: We believe that higher profitability will translate into cash flow from operations of $1.2 million in F2019 and $5.2 million in F2020. Concurrently, we expect cash will reach $2.3 million at the end of F2019 and $7.7 million at the end of F2020. Further, we anticipate CSBR will continue to remain debt-free and will not fund its growth plans through external financing
Valuation: We believe that Champions is under-valued based on our price target of $17 a share. A discounted cash flow model would yield a value of $18.00 a share based on a discount rate of 10.8% and a terminal value of $12.5 a share, by our estimates. We assume that the company will start paying taxes in 2024, and will generate free cash flow of over $37 million in F2028. Based on an Enterprise Value to Sales multiple of 6x calendar 2020 revenues of $37.0 million, this would peg shares at a $16.00 valuation. Our $17 price target reflects an average of these two valuation methods. Our multiple reflects a slightly premium to small, fast growing life sciences companies that offer proprietary products and services for the oncology market.
" (2/27/2019)
Has Champions Oncology been receiving favorable news coverage?
Media stories about CSBR stock have trended somewhat positive on Saturday, InfoTrie Sentiment reports. The research firm identifies positive and negative press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Champions Oncology earned a media sentiment score of 0.5 on InfoTrie's scale. They also gave news stories about the biotechnology company a news buzz of 2.0 out of 10, indicating that recent press coverage is very unlikely to have an impact on the stock's share price in the near future.
Who are some of Champions Oncology's key competitors?
Some companies that are related to Champions Oncology include Mesoblast (MESO), Avrobio (AVRO), Translate Bio (TBIO), Adaptimmune Therapeutics (ADAP), Agenus (AGEN), Adverum Biotechnologies (ADVM), Solid Biosciences (SLDB), Krystal Biotech (KRYS), Gritstone Oncology (GRTS), Cellular Biomedicine Group (CBMG), CASI Pharmaceuticals (CASI), Gamida Cell (GMDA), Novavax (NVAX), Eiger Biopharmaceuticals (EIGR) and Harpoon Therapeutics (HARP).
What other stocks do shareholders of Champions Oncology own?
Who are Champions Oncology's key executives?
Champions Oncology's management team includes the folowing people:
- Dr. Ronnie Morris, CEO & Director (Age 53)
- Mr. David Barry Miller, Chief Financial Officer (Age 50)
- Dr. Philip P. Breitfeld, Chief Strategy & Innovation Officer and Director (Age 66)
- Mr. Mark Weinstein, Chief Information Officer
- Mr. Bruce Ruggeri, Chief Scientific Officer
Who are Champions Oncology's major shareholders?
Champions Oncology's stock is owned by a variety of of institutional and retail investors. Top institutional investors include BlackRock Inc. (1.09%), Acadian Asset Management LLC (0.93%), Granite Investment Partners LLC (0.89%), Tocqueville Asset Management L.P. (0.69%), Essex Investment Management Co. LLC (0.64%) and Dimensional Fund Advisors LP (0.61%). Company insiders that own Champions Oncology stock include Daniel Newman Mendelson, Joel Ackerman and Ronnie Morris. View Institutional Ownership Trends for Champions Oncology.
Which major investors are selling Champions Oncology stock?
CSBR stock was sold by a variety of institutional investors in the last quarter, including Granite Investment Partners LLC, Millennium Management LLC, Tocqueville Asset Management L.P. and Essex Investment Management Co. LLC. Company insiders that have sold Champions Oncology company stock in the last year include Daniel Newman Mendelson and Joel Ackerman. View Insider Buying and Selling for Champions Oncology.
Which major investors are buying Champions Oncology stock?
CSBR stock was bought by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP, Dimensional Fund Advisors LP, Bank of New York Mellon Corp, Oberweis Asset Management Inc., Acadian Asset Management LLC, Alambic Investment Management L.P., Sandy Spring Bank and Squarepoint Ops LLC. View Insider Buying and Selling for Champions Oncology.
How do I buy shares of Champions Oncology?
Shares of CSBR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Champions Oncology's stock price today?
One share of CSBR stock can currently be purchased for approximately $10.09.
How big of a company is Champions Oncology?
Champions Oncology has a market capitalization of $117.14 million and generates $20.24 million in revenue each year. The biotechnology company earns $-1,470,000.00 in net income (profit) each year or ($0.14) on an earnings per share basis. Champions Oncology employs 92 workers across the globe.
What is Champions Oncology's official website?
How can I contact Champions Oncology?
Champions Oncology's mailing address is One University Plaza Suite 307, Hackensack NJ, 07601. The biotechnology company can be reached via phone at 201-808-8400 or via email at [email protected]
MarketBeat Community Rating for Champions Oncology (NASDAQ CSBR)
MarketBeat's community ratings are surveys of what our community members think about Champions Oncology and other stocks. Vote "Outperform" if you believe CSBR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CSBR will underperform the S&P 500 over the long term. You may vote once every thirty days.
